Plum SEC
Menu
Korean Market
Privacy Policy
Korean Market
Star Rating
Reset (View All)
★★★★★
★★★★
★★★
★★
★
★
★
★★
★★★
★★★★
★★★★★
All Disclosures
Search
EXCH
Pharos iBio
★★
Pharos iBio Selected for Government AI Drug Development Project: 3.52B KRW Non-Dilutive Funding for Next-Generation EGFR-Resistant NSCLC Treatment, Positive for Shareholder Value
06/01/2026, 09:14 AM
PERI
Pharos iBio
★
Pharos iBio Q1 2026: PHI-101 Phase 1 Complete, Operating Loss Continues, Convertible Bond Burden
05/14/2026, 05:19 PM